Favipiravir is primarily used as an antiviral agent, especially in the treatment of influenza and other RNA viral infections. It works by inhibiting viral RNA polymerase, which prevents the virus from replicating inside host cells. Due to this mechanism, it has been investigated and used in various viral outbreaks, including pandemic influenza, Ebola, and more recently, COVID-19. In some countries, it has been authorized for emergency use in mild to moderate cases of COVID-19, particularly when other treatments are not suitable. Its broad-spectrum antiviral activity makes it a candidate for emerging RNA viruses, and it is also studied for use in combination therapies to enhance antiviral effectiveness. Favipiravir is taken orally, which allows for easy administration in outpatient settings, making it useful in controlling the spread of viral infections early in the course of disease.